Tissue Archiving May Preclude Prospective Data In Deciding Assay Utility
This article was originally published in The Gray Sheet
Executive Summary
Drug companies anticipating use of molecular assays to complement therapies under development could be encouraged to rely on tissue-banked specimen analyses in lieu of prospective, randomized trials demonstrating clinical utility